By understanding the intricate relationship between immune checkpoint molecules like PD-L1 and PD-L2 and the histological subtypes and grades of the disease, clinicians can tailor treatment regimens to target specific molecular pathways associated with tumour progression and immune evasion. The gene discussed is CD274; the disease is neoplasm.